Payment overview · 2025
General Payments
$1,050.04
59 reported records · 16 companies
Healthcare provider profile · identity verified
Emory Wade Walker, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HARTWELL, GA · NPI 1538182431
Verified facts
What the public records show
CMS Open Payments records show Emory Wade Walker, M.D. received $1,050.04 in general payments during 2025 across 59 reported records.
Novo Nordisk Inc accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus, Shingrix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $194.15 | 18.5% | 12 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $149.50 | 14.2% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $127.60 | 12.2% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $106.80 | 10.2% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $85.05 | 8.1% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $69.25 | 6.6% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $58.25 | 5.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.61 | 4.9% | 3 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $37.18 | 3.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.74 | 3.2% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $28.71 | 2.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.67 | 2.7% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $27.50 | 2.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.88 | 1.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.73 | 1.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $16.42 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,050.04 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $149.50 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $106.80 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $101.83 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $88.75 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.88 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $70.88 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $62.95 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.10 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $58.25 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $51.61 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.55 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.55 | 3 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $37.18 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $37.18 | 2 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $37.18 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $33.75 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.74 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.90 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $28.71 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $28.67 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $27.50 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.70 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 115 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 169 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 149 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 146 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 62 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
115 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
169 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
62 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
90 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
169 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
149 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
146 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
159 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
44 | 43 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 820 | 216 |
| Levothyroxine Sodium | Levothyroxine Sodium | 630 | 170 |
| Lisinopril | Lisinopril | 593 | 161 |
| Amlodipine Besylate | Amlodipine Besylate | 574 | 155 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 509 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 464 | 142 |
| Tramadol Hcl | Tramadol Hcl | 429 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 409 | 118 |
| Metformin Hcl | Metformin Hcl | 396 | 99 |
| Omeprazole | Omeprazole | 363 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 336 | 97 |
| Losartan Potassium | Losartan Potassium | 315 | 88 |
| Lorazepam | Lorazepam | 313 | 63 |
| Furosemide | Furosemide | 301 | 85 |
| Gabapentin | Gabapentin | 288 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 279 | 79 |
| Trazodone Hcl | Trazodone Hcl | 271 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 259 | 66 |
| Meloxicam | Meloxicam | 250 | 86 |
| Prednisone | Prednisone | 247 | 178 |
| Potassium Chloride | Potassium Chloride | 241 | 47 |
| Simvastatin | Simvastatin | 234 | 49 |
| Alprazolam | Alprazolam | 231 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 219 | 70 |
| Diclofenac Sodium | Diclofenac Sodium | 216 | 98 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 213 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 206 | 58 |
| Famotidine | Famotidine | 199 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 183 | 66 |
| Cefdinir | Cefdinir | 182 | 150 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 180 | 58 |
| Citalopram Hbr | Citalopram Hydrobromide | 178 | 49 |
| Baclofen | Baclofen | 169 | 50 |
| Jardiance | Empagliflozin | 169 | 33 |
| Montelukast Sodium | Montelukast Sodium | 168 | 47 |
| Allopurinol | Allopurinol | 167 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 160 | 40 |
| Eliquis | Apixaban | 159 | 28 |
| Azithromycin | Azithromycin | 157 | 131 |
| Zolpidem Tartrate | Zolpidem Tartrate | 151 | 28 |
| Mounjaro | Tirzepatide | 149 | 29 |
| Ozempic | Semaglutide | 146 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 141 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 38 |
| Diazepam | Diazepam | 122 | 27 |
| Glipizide | Glipizide | 120 | 31 |
| Carvedilol | Carvedilol | 118 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 116 | 23 |
| Farxiga | Dapagliflozin Propanediol | 115 | 30 |
| Glipizide Er | Glipizide | 115 | 29 |
| Clonazepam | Clonazepam | 111 | 19 |
| Pregabalin | Pregabalin | 111 | 32 |
| Temazepam | Temazepam | 111 | 18 |
| Buspirone Hcl | Buspirone Hcl | 110 | 27 |
| Sertraline Hcl | Sertraline Hcl | 108 | 35 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 100 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 99 | 43 |
| Atenolol | Atenolol | 98 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 27 |
| Xarelto | Rivaroxaban | 97 | 17 |
| Ezetimibe | Ezetimibe | 95 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 93 | 24 |
| Ondansetron Odt | Ondansetron | 92 | 47 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 90 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 90 | 19 |
| Bupropion Xl | Bupropion Hcl | 89 | 28 |
| Fenofibrate | Fenofibrate,micronized | 81 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 80 | 70 |
| Donepezil Hcl | Donepezil Hcl | 78 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 77 | 22 |
| Levofloxacin | Levofloxacin | 76 | 60 |
| Amoxicillin | Amoxicillin | 75 | 60 |
| Alendronate Sodium | Alendronate Sodium | 70 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 70 | 49 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 69 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 63 | 11 |
| Promethazine Hcl | Promethazine Hcl | 63 | 21 |
| Sucralfate | Sucralfate | 63 | 16 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 62 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 21 |
| Cephalexin | Cephalexin | 57 | 37 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 54 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 54 | 14 |
| Fluconazole | Fluconazole | 54 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 16 |
| Synthroid | Levothyroxine Sodium | 53 | 14 |
| Venlafaxine Hcl | Venlafaxine Hcl | 52 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 51 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 50 | 15 |
| Colchicine | Colchicine | 50 | 13 |
| Rybelsus | Semaglutide | 50 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 43 |
| Linzess | Linaclotide | 49 | 18 |
| Primidone | Primidone | 47 | suppressed |
| Mirtazapine | Mirtazapine | 46 | 12 |
| Spironolactone | Spironolactone | 45 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 12 |
| Metformin Hcl Er | Metformin Hcl | 44 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 44 | 43 |
| Enalapril Maleate | Enalapril Maleate | 43 | 11 |
| Ibuprofen | Ibuprofen | 43 | 13 |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 14 |
| Meclizine Hcl | Meclizine Hcl | 42 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 34 |
| Estradiol | Estradiol | 41 | suppressed |
| Vraylar | Cariprazine Hcl | 41 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 38 | 14 |
| Finasteride | Finasteride | 38 | suppressed |
| Quviviq | Daridorexant Hcl | 38 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Mupirocin | Mupirocin | 34 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Torsemide | Torsemide | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 30 | 20 |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | 11 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Nabumetone | Nabumetone | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 25 | 25 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 12 |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | 11 |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 14 |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nortrel | Norethindrone-Ethin. Estradiol | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,050.04 · 59 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, BEYFORTUS, BREZTRI, Dexcom G6 Transmitter, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, SHINGRIX, SKYCLARYS, TRINTELLIX, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error